Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
Resource Type
Authors
Nicola Cascavilla ; Monica Galli ; Mario Boccadoro ; Dominella Gangemi ; Silvia Mangiacavalli ; Massimo Offidani ; Anna Grazia Recchia ; Elena Zamagni ; Angelo Belotti ; Alessandra Pompa ; Claudio Cerchione ; Giuseppina Uccello ; Paola Curci ; Catello Califano ; Concetta Conticello ; Elena Rossi ; Maria Teresa Petrucci ; Valerio De Stefano ; Giovanni Tripepi ; Ugo Consoli ; Enrico Attingenti ; Marino Brunori ; Stelvio Ballanti ; Clelia Criscuolo ; Nicola Giuliani ; Michele Cavo ; Renato Zambello ; Vincenzo Ludovico Fraticelli ; Giorgina Specchia ; Angela Bonalumi ; Francesca Patriarca ; Nicola Di Renzo ; Alessandra Lombardo ; Salvatore Palmieri ; Elisabetta Antonioli ; Cirino Botta ; Agostina Siniscalchi ; Raffaella Stocchi ; Barbara Gamberi ; Ferdinando Frigeri ; Massimo Gentile ; Giuseppe Mele ; Ernesto Vigna ; Pellegrino Musto ; Donatella Vincelli ; Silvana Capalbo ; Annalisa Pitino ; Sara Bringhen ; Daniele Derudas ; Francesco Di Raimondo ; Massimo Martino ; Roberto Ria ; Alfredo Gagliardi ; Gianpaolo Marcacci ; Fortunato Morabito ; Stefano Rocco
Source
Haematologica
Subject
Oncology medicine.medical_specialty Elotuzumab, lenalidomide, dexamethasone, salvage therapy, multiple myeloma Salvage therapy Antibodies, Monoclonal, Humanized Antibodies Dexamethasone Efficacy Internal medicine Monoclonal Antineoplastic Combined Chemotherapy Protocols medicine Humans Progression-free survival Elotuzumab Letters to the Editor Elotuzumab, lenalidomide, dexamethasone, multiple myeloma Humanized Lenalidomide Multiple myeloma Retrospective Studies Salvage Therapy business.industry Retrospective cohort study Hematology medicine.disease Clinical trial Italy Multiple Myeloma business medicine.drug
Language
English